UroGen Pharma Ltd.
URGN
Updated: 24/09/2026, 00:11:34
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
No summaries found.
- Share price
- $41.63
- Market cap
- $2.03B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Elizabeth Barrett
- Employees
- 300
- IPO date
- 04/05/2017
- Beta
- 1.58
- Last dividend
- $0.00
- Day range
- $39.72 – $42.72
- 52-week range
- $15.86 – $50.81
- 1-day performance
- -2.64%
- 1-year performance
- 162.48%
- Current drawdown (1Y)
- -18.07%
- CIK
- 0001668243
- CUSIP
- N/A
- ISIN
- IL0011407140
- Created
- 07/12/2025, 14:53:32
- Last update
- 24/09/2026, 00:11:34
Track UroGen Pharma Ltd. with an AI analyst
See which prediction-market events move URGN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
The Motley Fool • STOCK • 14/06/2026, 13:14:38
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 10/06/2026, 16:42:17
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
GlobeNewsWire • STOCK • 02/06/2026, 10:00:00
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Globe News Wire • STOCK • 01/06/2026, 18:10:00
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
Seeking Alpha • STOCK • 17/05/2026, 16:30:41
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 15:20:45
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 06/05/2026, 20:01:17
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
GlobeNewsWire • STOCK • 08/04/2026, 10:00:00
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
GlobeNewsWire • STOCK • 30/03/2026, 10:00:00
UroGen Pharma Ltd. (NASDAQ:URGN) Performance and Strategic Initiatives
Market Data • Market Data • 02/03/2026, 21:05:50
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 02/03/2026, 11:10:25